Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

REVEALED: Bristol myers expands cell therapy portfolio with orbital therapeutics acquisition | Vintage Vibes

Rueil-malmaison,,France,-,August,13,,2023:,French,Headquarters,Of,Bristol-myers

Bristol Myers Squibb & Co. (NYSE:BMY) on Friday agreed to acquire Orbital Therapeutics, a privately held biotechnology company focused on RNA medicines that reprogram the immune system in vivo.

The US drug giant agreed to pay $1.5 billion in cash.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.